Cardiac contractility modulation is a therapy which is intended for the treatment of patients with moderate to severe heart failure (NYHA class II–IV) with symptoms despite optimal medical …

2022年3月14日 · CCM therapy delivers nonexcitatory biphasic electric signals (7.5 V/22 ms duration) to the right ventricular septum during the absolute refractory period of the cardiac …

2024年1月31日 · One of the newer ways providers treat those with heart failure is cardiac contractility modulation, or CCM. CCM is a device-based therapy to treat patients with …

ECG aspect of a patient supported with a cardiac resynchronization therapy and defibrillator (CRT-D) and CCM. Despite the enlarged QRS, the CCM therapy was delivered, and one may …

2018年12月10日 · CCM signals have been shown to induce an acute, mild augmentation of left ventricular (LV) contractile strength without an increase in myocardial oxygen consumption in …

the CCM signal is applied during the absolute refractory period, as a pulse train at a short delay (typically 30 ms) after local sense in the ven-tricles, it typically shows on a body surface …

2023年11月1日 · Cardiac contractility modulation (CCM) is indicated in patients with NYHA class III and LVEF 25% to 45%. CCM provides excitatory stimulation to augment myocardial …

Cardiac contractility modulation (CCM) has been shown to benefit patients with class III systolic heart failure with an ejection fraction of 25%–45% not indicated for biventricular pacing. …

In chronic heart failure models, CCM treatment increases EF, SV, and LV dP/dt, and retards increases in LVEDV and LVESV, while frankly decreasing LVEDP (Fig. 7). Thus, CCM …

2020年10月10日 · Device-based therapy utilizing cardiac contractility modulation (CCM™) was approved by the FDA in March 2019 for patients with moderately to severely symptomatic …